TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2021

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.